DGAP-News: Bogar's Board extended with industry expert - New Value participates in capital increase


NEW VALUE AG / Miscellaneous

11.05.2010 07:02 

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bogar AG, a portfolio company of New Value, (SIX: NEWN), nominates to elect
Peter Haensli as new Board member on the occasion of an upcoming
shareholders meeting. Mr Haensli is a longtime pet industry expert.
Moreover, Bogar successfully closed a financing round of CHF 1.3 million.
New Value participated with CHF 0.75 million and is now holding a
31.6%-stake in Bogar's share capital. Bogar introduces its new products at
the Interzoo 2010, the world's leading pet industry exhibition.  Among the
new products are biocidals and herbal food supplies, especially a
one-of-a-kind anti-accarid gel for pets.

Bogar, a specialist for future-oriented animal health and food products
based on herbal ingredients, plans to strengthen the Board and prepares for
the next growth phase. At the upcoming extraordinary shareholders meeting
in June 2010, the management proposes to elect Peter Haensli as Board
member. It is intended by the company, that he will be appointed chairman
of the board. Peter Haensli is a longtime pet industry expert and former
Board member of Vitakraft, responsible for sales and logistics. He was also
CEO of Vitakraft International AG Switzerland. Vitakraft ist a major brand
name in the pet industry with 2,400 staff members and a turnover of EUR 300
million in Europe, USA and Asia. Bogar's management will be actively
supported by Peter Haensli and will benefit from his longterm experience in
marketing and sales. 'Bogar is a fascinating growth story with great
potential. I hope to be able to bring in my longterm experience in the most
profitable ways and am looking forward to this new challenge with the
dedicated and competent Bogar team,' Mr Haensli comments.

At the end of April, Bogar successfully closed a financing round of CHF 1.3
million, where New Value participated with CHF 0.75 Million in both share
capital and convertible loans. The remaining financing is provided by other
existing as well as new investors. CEO Marius Fuchs comments 'We will use
the new funds to extend our product range and further develop the European
sales network.

At «Interzoo 2010», Bogar will introduce new products. This is the world's
leading pet industry exhibition taking place midmonth in Nuremberg,
Germany. In particular, Bogar presents the new 'bogadual(R)', a gentle
anti-flea agent for cats and dogs as well as a new anti-accarid gel. These
innovative products are based on the herbal component Margosa. The product
lines of food additives will be extended with 'bogafit(R) Anti-Aging',
based on ginseng and 'bogafit(R) Verdauung', based on artichoke for
digestion disorders. Including these novelties, the Bogar range now
involves more than 20 products for pets and horses.


Information about Bogar AG
Bogar specializes in natural and future-oriented animal health and
nutrition and develops, produces and markets quality plant-based food
supplements and care products. Bogar is a leader in the area of veterinary
phytotherapy and the developer of an ever-growing product catalog for
effective supportive nutrition and the natural prevention and treatment of
various somatic disorders and diseases in animals. The current product
range consists of effective nutritional supplements as well as high-quality
care preparations for dogs, cats and horses. Please find further
information at www.bogar.com

Information about New Value AG 
New Value, listed at the SIX Swiss Exchange, invests directly in promising
private companies in Switzerland and neighbouring countries with
above-average market and growth potential. As an investment company, New
Value promotes innovative business models with venture capital and
accompanies those to market success. The portfolio covers companies of
different stages of development, starting with the market introduction
phase up to medium-sized enterprises with stable profits. A broad
investment approach is deliberately followed regarding industry sectors.
The portfolio contains companies active in Cleantech and Healthcare. New
Value assigns great value to ethical business concepts and good corporate
governance while selecting their portfolio companies. Criteria such as
meaningfulness, social responsibility and ecological sustainability are
considered by New Value as decisive competitive advantages, which affect
and enhance the quality of products and services offered and thus,
facilitate an above average increase of value potential. Since the
formation of New Value, EPS Value Plus AG, Zurich, has served as investment
manager.



Kontakt:
Marcel Rogenmoser








11.05.2010 07:02 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]

---------------------------------------------------------------------------
 
Language:     English
Company:      NEW VALUE AG
              Bodmerstrasse 9
              8027 Zürich
              Schweiz
Phone:        +41-43-344 38 38
Fax:          +41-43-344 38 39
E-mail:       info@newvalue.ch
Internet:     www.newvalue.ch
ISIN:         CH0010819867
WKN:          552932
Listed:       Freiverkehr in Berlin, München, Düsseldorf, Stuttgart; Open
              Market in Frankfurt; Foreign Exchange(s) SIX
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------